JP2025508435A5 - - Google Patents
Info
- Publication number
- JP2025508435A5 JP2025508435A5 JP2024548743A JP2024548743A JP2025508435A5 JP 2025508435 A5 JP2025508435 A5 JP 2025508435A5 JP 2024548743 A JP2024548743 A JP 2024548743A JP 2024548743 A JP2024548743 A JP 2024548743A JP 2025508435 A5 JP2025508435 A5 JP 2025508435A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- disorders
- solvate
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2202199.2 | 2022-02-18 | ||
| GBGB2202199.2A GB202202199D0 (en) | 2022-02-18 | 2022-02-18 | Compounds |
| PCT/GB2023/050369 WO2023156791A1 (en) | 2022-02-18 | 2023-02-17 | Heterocyclic compounds useful for treating a erk5-mediated disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508435A JP2025508435A (ja) | 2025-03-26 |
| JP2025508435A5 true JP2025508435A5 (enExample) | 2026-01-08 |
Family
ID=80934460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548743A Pending JP2025508435A (ja) | 2022-02-18 | 2023-02-17 | Ｅｒｋ５媒介性疾患を治療するのに有用な複素環式化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250154157A1 (enExample) |
| EP (1) | EP4479400A1 (enExample) |
| JP (1) | JP2025508435A (enExample) |
| CN (1) | CN119053604A (enExample) |
| AU (1) | AU2023220934A1 (enExample) |
| CA (1) | CA3251985A1 (enExample) |
| GB (1) | GB202202199D0 (enExample) |
| WO (1) | WO2023156791A1 (enExample) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| JP2017504650A (ja) * | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体およびその使用 |
| WO2015117087A1 (en) * | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| WO2015129927A1 (en) * | 2014-02-26 | 2015-09-03 | Kyorin Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| EP4034132B1 (en) | 2019-09-27 | 2026-02-25 | Dana-Farber Cancer Institute, Inc. | Erk5 degraders as therapeutics in cancer and inflammatory diseases |
-
2022
- 2022-02-18 GB GBGB2202199.2A patent/GB202202199D0/en not_active Ceased
-
2023
- 2023-02-17 US US18/838,492 patent/US20250154157A1/en active Pending
- 2023-02-17 AU AU2023220934A patent/AU2023220934A1/en active Pending
- 2023-02-17 JP JP2024548743A patent/JP2025508435A/ja active Pending
- 2023-02-17 WO PCT/GB2023/050369 patent/WO2023156791A1/en not_active Ceased
- 2023-02-17 CA CA3251985A patent/CA3251985A1/en active Pending
- 2023-02-17 CN CN202380034888.8A patent/CN119053604A/zh active Pending
- 2023-02-17 EP EP23708272.2A patent/EP4479400A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512174A5 (enExample) | ||
| JP2021098728A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| JP2018513107A5 (enExample) | ||
| JP2017222722A5 (enExample) | ||
| JP2018109022A5 (enExample) | ||
| JP2022502500A5 (enExample) | ||
| JP2001526232A (ja) | 少なくとも一つのロイコトリエンアンタゴニストおよび少なくとも一つの抗ヒスタミン剤を含有する呼吸器および皮膚疾患処置のための組成物 | |
| RU2010108640A (ru) | Новая комбинация терапевтических агентов | |
| CN111035640B (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途 | |
| RU2015137978A (ru) | Способы ингибирования лейкотриен- а4-гидролазы | |
| JP2018168191A5 (enExample) | ||
| JP2020531463A5 (enExample) | ||
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2023156372A5 (enExample) | ||
| NZ547523A (en) | Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same | |
| JP2024516359A5 (enExample) | ||
| CN102488681A (zh) | 布洛芬苯海拉明口腔崩解片及其制备方法 | |
| JP2013537901A5 (enExample) | ||
| JP2005524666A5 (enExample) | ||
| JP2011520877A5 (enExample) | ||
| JP2021503448A5 (enExample) | ||
| FI4199922T3 (fi) | (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa | |
| JP2023538125A5 (enExample) | ||
| JP2009542609A5 (enExample) |